Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Amylin Pharmaceuticals
So what: Amylin saw its stock drop 50% last week when regulators declined to approve Bydureon. The stock may have oversold on that news, and analysts think it still has upside even with a longer lead time on the diabetes treatment.
Now what: Bydureon still has a long road ahead and this Fool never likes buying because an analyst says so. This looks like a typical upgrade bump to me, without any solid news from the company. I'm selling the move today given the long-term uncertainty surrounding Bydureon.
Interested in more info on Amylin Pharmaceuticals? Add it to your watchlist here by clicking here.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community. The Motley Fool has a disclosure policy.